Zymeworks Inc. will participate in investor conferences on November 11 and 17-19, 2025, in New York and London, respectively.
Quiver AI Summary
Zymeworks Inc., a clinical-stage biotechnology firm based in Vancouver, announced participation in two upcoming investor conferences: the Stifel Healthcare Conference on November 11 in New York and the Jefferies London Healthcare Conference from November 17-19 in London. The company focuses on developing novel biotherapeutics to treat challenging diseases such as cancer, inflammation, and autoimmune disorders. Notably, Zymeworks recently received various approvals for zanidatamab, a bispecific antibody targeting HER2, which is now the first of its kind approved for certain types of cancer in the U.S., Europe, and China. The company is also advancing other candidates in its pipeline and has established strategic partnerships to enhance its therapeutic platforms. For more information, they encourage visits to their website and social media.
Potential Positives
- Participation in major investor conferences, such as Stifel Healthcare Conference and Jefferies London Healthcare Conference, suggests active engagement with the investment community.
- Zanidatamab's accelerated approval by the U.S. FDA and conditional approvals in China and Europe indicates significant product advancement and market potential.
- Zymeworks' commitment to developing a diverse pipeline of biotherapeutics for hard-to-treat diseases could position the company as a leader in innovation within its field.
- The company's strategic partnerships for the development and commercialization of zanidatamab demonstrate strong collaborative efforts and expansion of market reach.
Potential Negatives
- Management's upcoming participation in investor conferences may signal a need for increased investor engagement, indicating potential concerns about investor confidence or company performance.
- The completion of clinical trials and the status of pipeline products are not specifically addressed, which could raise questions about the progress and viability of their drug development efforts.
- While zanidatamab has received conditional approvals, its reliance on these approvals may suggest uncertainty regarding its long-term market success and potential commercial challenges ahead.
FAQ
What is Zymeworks Inc. known for?
Zymeworks Inc. is a biotechnology company focused on developing multifunctional biotherapeutics for difficult-to-treat diseases like cancer and autoimmune disorders.
When will Zymeworks participate in investor conferences?
Zymeworks will participate in the Stifel Healthcare Conference on November 11, 2025, and the Jefferies London Healthcare Conference from November 17-19, 2025.
What is zanidatamab?
Zanidatamab is a HER2-targeted bispecific antibody developed by Zymeworks, approved for treating HER2-positive biliary tract cancer.
Which markets have approved zanidatamab?
Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization in Europe.
What new developments are expected from Zymeworks?
Zymeworks anticipates clinical trials for ZW251 to begin in 2025 and is actively recruiting for a Phase 1 study of ZW191.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZYME Insider Trading Activity
$ZYME insiders have traded $ZYME stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 2 purchases buying 55,421 shares for an estimated $635,585 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZYME Hedge Fund Activity
We have seen 90 institutional investors add shares of $ZYME stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 5,710,840 shares (+33.1%) to their portfolio in Q2 2025, for an estimated $71,671,042
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,420,432 shares (-36.6%) from their portfolio in Q2 2025, for an estimated $17,826,421
- ASSENAGON ASSET MANAGEMENT S.A. added 833,994 shares (+169.2%) to their portfolio in Q3 2025, for an estimated $14,244,617
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 766,944 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $9,625,147
- VANGUARD GROUP INC added 697,652 shares (+39.5%) to their portfolio in Q2 2025, for an estimated $8,755,532
- VESTAL POINT CAPITAL, LP added 650,000 shares (+130.0%) to their portfolio in Q2 2025, for an estimated $8,157,500
- REDMILE GROUP, LLC removed 638,318 shares (-13.3%) from their portfolio in Q2 2025, for an estimated $8,010,890
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZYME Analyst Ratings
Wall Street analysts have issued reports on $ZYME in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 10/10/2025
- Citigroup issued a "Buy" rating on 08/11/2025
- TD Securities issued a "Buy" rating on 05/20/2025
To track analyst ratings and price targets for $ZYME, check out Quiver Quantitative's $ZYME forecast page.
$ZYME Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 5 analysts offer price targets for $ZYME in the last 6 months, with a median target of $23.0.
Here are some recent targets:
- Eva Fortea Verdejo from Wells Fargo set a target price of $15.0 on 10/24/2025
- Brian Cheng from JP Morgan set a target price of $23.0 on 10/16/2025
- Robert Burns from HC Wainwright & Co. set a target price of $26.0 on 10/14/2025
- Mayank Mamtani from B. Riley Securities set a target price of $30.0 on 10/10/2025
- Yigal Nochomovitz from Citigroup set a target price of $22.0 on 08/11/2025
Full Release
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
- Stifel Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 11, 2025, in New York, NY.
-
Jefferies London Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 17- 19, 2025, in London, UK.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. A Phase 1 study for ZW191 is actively recruiting and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]
Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]
